» Articles » PMID: 20133787

Analysis of the Cellular Mechanism Underlying Inhibition of EAE After Treatment with Anti-NKG2A F(ab')2

Overview
Specialty Science
Date 2010 Feb 6
PMID 20133787
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmune encephalomyelitis may be ameliorated experimentally by enhancing NK cell-mediated elimination of activated autoreactive T cells through a mutation that interrupts the interaction between Qa-1(b) and CD94/NKG2A. Here we evaluate the ability of an anti-NKG2A F(ab')(2) Ab to enhance elimination of autoreactive T cells and reduce experimental autoimmune encephalomyelitis (EAE). Anti-NKG2A F(ab')(2) treatment diminishes progression of both myelin oligodendrocyte glycoprotein (MOG)-induced EAE in intact C57BL/6 mice and after adoptive transfer of disease-causing T cells. Analyses of the underlying mechanism revealed that administration of anti-NKG2A F(ab')(2) Ab reduces CD4(+) T recall responses to MOG and skews the proportion of IL-17- and IFNgamma-producing CD4(+) T cells toward the protective IL-4- and IL-10-secreting CD4(+) T cell subpopulations. CD94/NKG2A-dependent inhibition of inflammatory damage to spinal cord is associated with decreased infiltration of T cells and reduced microglia activation in the central nervous system. Because anti-NKG2A F(ab')(2) treatment had no detectable effect on the numbers or activity of T and B lymphocytes and NK cells in peripheral lymphoid tissues, this anti-NKG2A-based approach may represent a safe and effective therapy for this CNS disorder.

Citing Articles

LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity.

Ngiow S, Manne S, Huang Y, Azar T, Chen Z, Mathew D Cell. 2024; 187(16):4336-4354.e19.

PMID: 39121847 PMC: 11337978. DOI: 10.1016/j.cell.2024.07.018.


Distinctive CD56 NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson's disease patients.

Weber S, Menees K, Park J, Agin-Liebes J, Lin C, Alcalay R NPJ Parkinsons Dis. 2024; 10(1):36.

PMID: 38360903 PMC: 10869354. DOI: 10.1038/s41531-024-00652-y.


Implications of NKG2A in immunity and immune-mediated diseases.

Wang X, Xiong H, Ning Z Front Immunol. 2022; 13:960852.

PMID: 36032104 PMC: 9399941. DOI: 10.3389/fimmu.2022.960852.


Interaction Between Innate Lymphoid Cells and the Nervous System.

Zhang Y, Grazda R, Yang Q Adv Exp Med Biol. 2022; 1365:135-148.

PMID: 35567745 DOI: 10.1007/978-981-16-8387-9_9.


NK Cells in Autoimmune Diseases: Protective or Pathogenic?.

Liu M, Liang S, Zhang C Front Immunol. 2021; 12:624687.

PMID: 33777006 PMC: 7994264. DOI: 10.3389/fimmu.2021.624687.


References
1.
Lublin F . Adoptive transfer of murine relapsing experimental allergic encephalomyelitis. Ann Neurol. 1985; 17(2):188-90. DOI: 10.1002/ana.410170214. View

2.
Takeda K, Oshima H, Hayakawa Y, Akiba H, Atsuta M, Kobata T . CD27-mediated activation of murine NK cells. J Immunol. 2000; 164(4):1741-5. DOI: 10.4049/jimmunol.164.4.1741. View

3.
Chan A, Westcott J, Mooney J, Wakeland E, Schatzle J . The role of SAP and the SLAM family in autoimmunity. Curr Opin Immunol. 2006; 18(6):656-64. DOI: 10.1016/j.coi.2006.09.010. View

4.
Sullivan L, Clements C, Beddoe T, Johnson D, Hoare H, Lin J . The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition. Immunity. 2007; 27(6):900-11. DOI: 10.1016/j.immuni.2007.10.013. View

5.
Steinman L, Martin R, Bernard C, Conlon P, Oksenberg J . Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci. 2002; 25:491-505. DOI: 10.1146/annurev.neuro.25.112701.142913. View